Vertex Pharmaceuticals Incorporated  

(Public, NASDAQ:VRTX)   Watch this stock  
Find more results for Joshua I. Smith
118.08
-0.82 (-0.69%)
Real-time:   12:54PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 116.00 - 122.17
52 week 59.79 - 124.35
Open 118.92
Vol / Avg. 1.04M/1.58M
Mkt cap 28.51B
P/E     -
Div/yield     -
EPS -2.21
Shares 240.52M
Beta 0.33
Inst. own 98%
Jan 27, 2015
Q4 2014 Vertex Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 2, 2014
Vertex Pharmaceuticals Inc at Deutsche Bank BioFEST
Nov 11, 2014
Vertex Pharmaceuticals Inc at Credit Suisse Healthcare Conference
Oct 28, 2014
Q3 2014 Vertex Pharmaceuticals Inc Earnings Call - Webcast
Oct 28, 2014
Q3 2014 Vertex Pharmaceuticals Inc Earnings Release
Oct 10, 2014
Vertex Pharmaceuticals Inc NACF Investor Event
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -94.98% -56.73%
Operating margin -79.45% -74.54%
EBITD margin - 6.49%
Return on average assets -30.14% -27.08%
Return on average equity -58.57% -37.78%
Employees 1,800 -
CDP Score - -

Address

50 Northern Avenue
BOSTON, MA 02210
United States - Map
+1-617-3416393 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases. The Company�s two products are INCIVEK (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus (HCV), infection, and KALYDECO (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis (CF), who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), gene. The Company has ongoing clinical programs involving drug candidates intended for the treatment of HCV infection, CF, rheumatoid arthritis, influenza and epilepsy. INCIVEK (telaprevir) achieved initial commercial acceptance following its approval in May 2011. It started marketing KALYDECO in the United States in January 2012.

Officers and directors

Jeffrey M. Leiden M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer
Bio & Compensation  - Reuters
Ian F. Smith CPA Chief Financial Officer, Executive Vice President
Age: 48
Bio & Compensation  - Reuters
Stuart A. Arbuckle Executive Vice President, Chief Commercial Officer
Age: 48
Bio & Compensation  - Reuters
Jeffrey A. Chodakewitz M.D. Chief Medical Officer and Senior Vice President - Global Medicines Development
Bio & Compensation  - Reuters
Kenneth L. Horton Executive Vice President, Chief Legal Officer
Age: 47
Bio & Compensation  - Reuters
Paul M. Silva Senior Vice President, Corporate Controller
Age: 48
Bio & Compensation  - Reuters
Thomas F. Connolly Senior Vice President, Director of Human Resources
Age: 56
Bio & Compensation  - Reuters
Megan Pace Senior Vice President - Corporate Communications
Age: 41
Bio & Compensation  - Reuters
Amit K. Sachdev J.D. Senior Vice President - Global Government Strategy, Market Access and Value
Age: 46
Bio & Compensation  - Reuters
Bruce I. Sachs Co-Lead Independent Director
Age: 54
Bio & Compensation  - Reuters